This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Media Advisory

Stocks in this article: GE

GE (NYSE: GE):

What:

  On Monday, March 11, NFL Commissioner Roger Goodell and GE Chairman and CEO Jeff Immelt will unveil details of a new initiative to study concussions and improve player safety through a research and innovation program.
 
A medical panel will immediately follow discussing the need for research and its impact on healthcare, sports and society as a whole.
 

Who:

Jeff Immelt, Chairman and CEO, GE
Roger Goodell, Commissioner, NFL
Lt. Gen. Patricia D. Horoho, Surgeon General of the Army and Commanding General of the United States Army Medical Command
Sue Siegel, CEO healthymagination, GE
Richard Hausmann, President and CEO, MR, GE Healthcare
Dr. Geoffrey Manley, UCSF
Dr. Russell Lonser, member, NFL Head, Neck and Spine Committee/Chair, Department of Neurological Surgery, Ohio State University
Mark Emmert, president, NCAA
Charlotte Anderson, Dallas Cowboys and Chair, NFL Foundation
Woody Johnson, New York Jets
Robert Kraft, New England Patriots
John Mara, New York Giants
Rich McKay, Atlanta Falcons and Chair, NFL Competition Committee
Dr. John York, San Francisco 49ers and Chair, NFL Health & Safety Advisory Committee
 

When:

Monday, March 11, 2013 1:00 -2:00 p.m. ET
 

Where:

GE
30 Rockefeller Plaza, 52 nd Floor
New York, NY 10112

If you are interested in attending the event, please email megan.parker@ge.com



Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,672.60 -141.38 -0.79%
S&P 500 2,051.82 -11.33 -0.55%
NASDAQ 4,757.8790 +7.4820 0.16%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs